BIOMAT Database Logo BIOMAT Database Logo

[A year of treatment with carbidopa and levodopa in Parkinsonian patients]. 1974

J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Electroencephalographic change in Parkinsonian patients treated with levodopa-carbidopa.
January 1979, Clinical EEG (electroencephalography),
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Plasma levels of levodopa. Its main metabolites and carbidopa after conventional and slow release levodopa-carbidopa treatment in parkinsonian patients.
January 1990, Pharmacological research,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
February 1989, Clinical neuropharmacology,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
November 1989, Neurology,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
September 1999, British journal of clinical pharmacology,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
December 1995, Biological & pharmaceutical bulletin,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.
January 2014, Parkinsonism & related disorders,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants.
May 1990, Neurology,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
December 1993, Neurology,
J M Martínez-Lage, and J F Marti-Massó, and G Delgado, and N Carreray, and F Del Amo
Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.
June 1988, Italian journal of neurological sciences,
Copied contents to your clipboard!